APX3330, An Oral Tablet for Treatment of Diabetic Retinopathy

Time: 5:30 pm
day: Day One

Details:

  • Ref-1, Novel target for retinal diseases
  • Safety data across 11 Phase 1 and Phase 2 clinical trials
  • Ongoing clinical trial design

Speakers: